AP1956A - y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it - Google Patents

y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it

Info

Publication number
AP1956A
AP1956A AP2006003521A AP2006003521A AP1956A AP 1956 A AP1956 A AP 1956A AP 2006003521 A AP2006003521 A AP 2006003521A AP 2006003521 A AP2006003521 A AP 2006003521A AP 1956 A AP1956 A AP 1956A
Authority
AP
ARIPO
Prior art keywords
preperation
pharmaceutical compositions
crystalline form
compositions containing
ivabradine hydrochloride
Prior art date
Application number
AP2006003521A
Other languages
English (en)
Other versions
AP2006003521A0 (en
Inventor
Stephanie Horvath
Marie-Noelle Auguste
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP1956(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2006003521A0 publication Critical patent/AP2006003521A0/xx
Application granted granted Critical
Publication of AP1956A publication Critical patent/AP1956A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2006003521A 2005-02-28 2006-02-22 y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it AP1956A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
AP2006003521A0 AP2006003521A0 (en) 2006-02-28
AP1956A true AP1956A (en) 2009-02-18

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003521A AP1956A (en) 2005-02-28 2006-02-22 y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it

Country Status (42)

Country Link
US (3) US7361650B2 (zh)
EP (1) EP1707562B1 (zh)
JP (1) JP4628974B2 (zh)
KR (1) KR100835447B1 (zh)
CN (1) CN100402502C (zh)
AP (1) AP1956A (zh)
AR (1) AR052926A1 (zh)
AT (1) ATE396974T1 (zh)
BR (1) BRPI0600796B8 (zh)
CA (1) CA2537400C (zh)
CO (1) CO5770097A1 (zh)
CR (1) CR8249A (zh)
CU (1) CU23616B7 (zh)
CY (1) CY1109010T1 (zh)
DE (1) DE602006001312D1 (zh)
DK (1) DK1707562T3 (zh)
EA (1) EA008465B1 (zh)
ES (1) ES2308689T3 (zh)
FR (1) FR2882555B1 (zh)
GE (1) GEP20084467B (zh)
GT (1) GT200600088A (zh)
HK (1) HK1096659A1 (zh)
HR (1) HRP20080406T5 (zh)
IL (1) IL173959A0 (zh)
JO (1) JO2515B1 (zh)
MA (1) MA28134A1 (zh)
ME (1) ME02747B (zh)
MY (1) MY158129A (zh)
NO (1) NO338481B1 (zh)
NZ (1) NZ545578A (zh)
PE (1) PE20061142A1 (zh)
PL (1) PL1707562T3 (zh)
PT (1) PT1707562E (zh)
RS (1) RS50598B (zh)
SA (1) SA06270040B1 (zh)
SG (1) SG125229A1 (zh)
SI (1) SI1707562T1 (zh)
TW (1) TWI314143B (zh)
UA (1) UA86595C2 (zh)
UY (1) UY29406A1 (zh)
WO (1) WO2006092492A1 (zh)
ZA (1) ZA200601764B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
PT2471780E (pt) 2007-05-30 2015-02-24 Ind Swift Lab Ltd Sais oxalato de ivabradina cristalinos e seus polimorfos
CN102264689B (zh) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2534135A2 (en) 2010-02-12 2012-12-19 KRKA, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2773621B1 (en) 2011-11-04 2015-12-30 Synthon BV A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
SI2781509T2 (sl) * 2013-03-19 2023-10-30 Chemo Research, S.L. Novi polimorf ivabradin hidroklorida in postopek za njegovo pripravo
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
WO2020092288A1 (en) 2018-10-30 2020-05-07 Amgen Inc. Process of making ivabradine hydrochloride drug product
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534859A1 (fr) * 1991-09-27 1993-03-31 Adir Et Compagnie 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534859A1 (fr) * 1991-09-27 1993-03-31 Adir Et Compagnie 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires

Also Published As

Publication number Publication date
US20080153803A1 (en) 2008-06-26
CR8249A (es) 2008-01-21
AR052926A1 (es) 2007-04-11
MA28134A1 (fr) 2006-09-01
UY29406A1 (es) 2006-07-31
NO20060948L (no) 2006-08-29
EP1707562A1 (fr) 2006-10-04
EP1707562B1 (fr) 2008-05-28
ME02747B (me) 2010-05-07
DK1707562T3 (da) 2008-10-13
DE602006001312D1 (de) 2008-07-10
IL173959A0 (en) 2006-07-05
AU2006200857A1 (en) 2010-01-28
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
HRP20080406T5 (en) 2008-11-30
GT200600088A (es) 2006-10-24
CU23616B7 (es) 2011-01-27
FR2882555A1 (fr) 2006-09-01
GEP20084467B (en) 2008-08-25
PL1707562T3 (pl) 2008-08-29
US7867996B2 (en) 2011-01-11
PE20061142A1 (es) 2006-12-30
TW200640872A (en) 2006-12-01
CA2537400C (fr) 2009-12-15
BRPI0600796A (pt) 2007-08-14
PT1707562E (pt) 2008-07-08
CU20060037A7 (es) 2008-06-30
ATE396974T1 (de) 2008-06-15
HK1096659A1 (en) 2007-06-08
NZ545578A (en) 2007-02-23
MY158129A (en) 2016-08-30
FR2882555B1 (fr) 2007-05-04
WO2006092492A1 (fr) 2006-09-08
BRPI0600796B1 (pt) 2019-02-19
US20090318417A1 (en) 2009-12-24
SG125229A1 (en) 2006-09-29
NO338481B1 (no) 2016-08-22
SI1707562T1 (sl) 2008-10-31
JP4628974B2 (ja) 2011-02-09
CO5770097A1 (es) 2007-06-29
ZA200601764B (en) 2007-05-30
CY1109010T1 (el) 2014-07-02
RS50598B (sr) 2010-05-07
US7361650B2 (en) 2008-04-22
KR20060095499A (ko) 2006-08-31
SA06270040B1 (ar) 2010-03-23
EA200600320A1 (ru) 2006-08-25
EA008465B1 (ru) 2007-06-29
BRPI0600796B8 (pt) 2021-05-25
US20060194963A1 (en) 2006-08-31
JP2006241156A (ja) 2006-09-14
CN1827602A (zh) 2006-09-06
HRP20080406T3 (en) 2008-09-30
TWI314143B (en) 2009-09-01
KR100835447B1 (ko) 2008-06-09
ES2308689T3 (es) 2008-12-01
UA86595C2 (ru) 2009-05-12
JO2515B1 (en) 2010-03-17
AP2006003521A0 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
AP1956A (en) y-Crystalline form of Ivabradine Hydrochloride, a process for its preperation and pharmaceutical compositions containing it
TWI315306B (en) Bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
HK1096387A1 (en) ß-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
ZA200608404B (en) Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
SG131858A1 (en) delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
ZA200601760B (en) Yd-crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical compositions containing it
ZA200606455B (en) Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HK1096386A1 (en) Indanyl-piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200603810B (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
HK1096097A1 (en) Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
HK1093986A1 (en) Piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
IL192963A0 (en) Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
EP1948162A4 (en) PHARMACEUTICAL COMPOSITIONS WITH ERYTHRINE-MULUNGU DERIVATIVES AND METHOD OF MANUFACTURE
IL189177A0 (en) Process for producing carcosporamide and pharmaceutical compositions containing cercosporamide
ZA200800833B (en) New 1H-indole-pyridinecarboxamide and 1H-indolepiperidinecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them
AU2006200857B2 (en) y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200854B2 (en) bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200856B2 (en) beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it